Turn your High-Throughput-Screening project into a Focused-Screening
High Throughput Screening (HTS) is the experimental method predominantly used today in drug discovery process. In this process, typically 50.000 to 200.000 compounds are screened, in small containers for observation of reactions between compound and target.
The HTS is typically performed in pilot, primary and a secondary phase, where in average 200.000 compounds are screened. HTS is more like looking for a needle in the haystack and the initial choice of the search area, has a major impact of the success ratio of the search.
Some of the major challenges in the screening process is knowing if right compounds are used and the need to cover a wide range of the chemical space to understand the biological function.
pharmAI's Focused Screening
pharmAI's innovative solution, based on binding site analysis, decreases the screening space dramatically. pharmAIs algorithms, provide the drug developers with predictions of one or multiple constrained compound space(s) that can easily be related to compound library manufacturers for cherry picking.
Our DiscoveryEngine can hence shorten the drug discovery process, short-cutting and optimizing the screening process, for better results at a lower cost at the same time as enriching the diversification of scaffolds relevant for the search.
Yet another advantage of using pharmAI services is the off-target analysis and prediction provided that can otherwise be challenging in the conventional drug discovery process.